Contact PI/Project LeaderHANSON, MAUREEN REBECCA Other PIs
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
Project Summary: Overall
Despite the enormous suffering endured by millions of people worldwide, the underlying causes of Myalgic
Encephalomyelitis/ChronicFatigueSyndrome (ME/CFS) are unknown and effective therapies are lacking.
ME/CFS is characterized by debilitating fatigue, musculoskeletal pain, headaches, cognitive difficulties
orthostatic intolerance, and sleep disturbances. The absence of simple objective tests prevents many from
obtaining an appropriate diagnosis and inhibits drug development because of the lack of biomarkers to monitor
the efficacy of experimental therapies. In order to gain fundamental mechanistic insights into ME/CFS, we will
leverage the experience, capabilities and varied backgrounds of researchers from four different colleges at
Cornell University, Florida Atlantic University, the Hospital for Special Surgery, and an ME/CFS expert
physician. We will take advantage of an enormous amount of data already obtained from patients and controls
both before and after symptom provocation through exercise, as well as a valuable set of new samples. Three
research projects will seek to (1) use cutting-edge multi-omic single cell profiling to examine alterations in cell
types, gene expression, and cell-cell interactions that occur in ME/CFS muscle (Project 1), (2) identify tissue
injured in ME/CFS following exercise through characterization of RNA released into circulation and (3) identify
the RNA and protein cargo of extracellular vesicles in ME/CFS patients that may alter function of target cells
(Project 2) and (4) Use genomic and computational methods to better understand the gene regulatory
mechanisms that result in immune dysregulation in ME/CFS and systematically identify ME/CFS-specific
alterations in signaling across the immune system (Project 3). These three research projects are supported
by a Research Core that will act as a resource for genomics technology expertise, reagents, and services and
for data management and integrated analysis. Multi-omic analysis and predictive modeling carried out in all
three Projects will provide a foundation for future development of therapeutics and diagnostic tests. All Center
activities will be coordinated through an Administrative Core, which will foster synergy and integration within
the Center, while also being the platform for collaboration with other ME/CFS Collaborative Research Centers,
a Patient/Advocate/Caregiver Committee, other ME/CFS researchers, and the Data Management Coordinating
Center. The Administrative Core will also be responsible for outreach activities that are designed to increase
awareness and understanding of ME/CFS within the research community, health professionals, and the
general public, and will administer a pilot project program designed to bring new ideas and researchers into the
ME/CFS field.
Public Health Relevance Statement
Project Narrative
Myalgic encephalomyelitis/chronicfatiguesyndrome (ME/CFS) is a serious, debilitating illness whose
molecular basis is not understood, preventing development of simple diagnostic tests and endpoints for
evaluating therapies in clinical trials. This Center will bring together a multidisciplinary team with expertise in
immunology, muscle biology, gene expression, cell-free RNA, extracellular vesicles, plasma protein
characterization, and computational analysis of large data sets. By assessing biospecimens from subjects at
baseline and following symptom exacerbation, the team will seek to understand the underlying
pathophysiology of ME/CFS and enhance knowledge of the lay public, patients, and health professionals
concerning the disease.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
872612445
UEI
G56PUALJ3KT5
CCV3WG2JG248
D4H1NV4APKP3
ELS2M3C6V2S5
EQA8NBEN9WD5
FFAZGE9NH3M8
K6JRCJJXFET1
M8FBSLHASMT3
P4LRVQT1H4K5
PJUVN8AT5416
RT1JPM9UMGM5
ZBMGUAZYFGC4
ZMP8BDLJTUW9
Project Start Date
30-September-2017
Project End Date
31-March-2028
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$1,866,110
Direct Costs
$1,616,603
Indirect Costs
$806,523
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$1,866,110
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54AI178855-07
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54AI178855-07
Patents
No Patents information available for 5U54AI178855-07
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54AI178855-07
Clinical Studies
No Clinical Studies information available for 5U54AI178855-07
News and More
Related News Releases
No news release information available for 5U54AI178855-07
History
No Historical information available for 5U54AI178855-07
Similar Projects
No Similar Projects information available for 5U54AI178855-07